Literature DB >> 31648999

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

Jaafar Bennouna1, Nicolas Girard2, Clarisse Audigier-Valette3, Aurélie le Thuaut4, Radj Gervais5, Philippe Masson6, Marie Marcq7, Olivier Molinier8, Alexis Cortot9, Didier Debieuvre10, Jacques Cadranel11, Hervé Lena12, Denis Moro-Sibilot13, Christos Chouaid14, Bertrand Mennecier15, Thierry Urban16, Christine Sagan17, Ludivine Perrier4, Fabrice Barlesi18, Marc G Denis19.   

Abstract

BACKGROUND: Osimertinib, a third-generation tyrosine kinase inhibitor, is a new therapeutic option in epidermal growth factor receptor (EGFR)-mutated non-pretreated advanced non-small-cell lung cancer (NSCLC). The tumor escape mechanisms after first-line treatment with osimertinib are partially known; most of the data being obtained by analysis of circulating tumor DNA (ctDNA) from the FLAURA phase III trial. STUDY
DESIGN: The MELROSE study, a French multicentric, open label, phase II trial (ClinicalTrials.govNCT03865511) plans to enroll 150 patients with treatment-naive advanced EGFR-mutated (L858R or exon 19 deletion) NSCLC, age ≥ 18 years, with an Eastern Cooperative Oncology Group performance status 0 or 1. All patients will receive osimertinib at the dose of 80 mg/d. Tumor assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria will be performed every 3 months, with brain and thoracoabdominal computed tomographic scan. The continuation of osimertinib is at the discretion of the referring physician, particularly if clinical benefit is observed. The primary objective is the genetic tumor profile, both on tissue biopsy and ctDNA analyses, at the time of disease progression. Other endpoints include kinetic studies of ctDNA, biological progression-free survival (bPFS) (time from first study dose to first biological event on ctDNA), median PFS according to RECIST criteria 1.1 (called radiological [r] PFS), and median clinical (c) PFS (time from the first study dose to off-osimertinib). This study started in April 2019, and 18 centers in France are participants.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EGFR mutation; Lung cancer; Resistance; Tissue biopsy; ctDNA

Mesh:

Substances:

Year:  2019        PMID: 31648999     DOI: 10.1016/j.cllc.2019.09.007

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  5 in total

Review 1.  The next tier of EGFR resistance mutations in lung cancer.

Authors:  Hannah L Tumbrink; Alena Heimsoeth; Martin L Sos
Journal:  Oncogene       Date:  2020-10-15       Impact factor: 9.867

Review 2.  Overcoming therapy resistance in EGFR-mutant lung cancer.

Authors:  Pasi A Jänne; Tony Mok; Solange Peters; Antonio Passaro
Journal:  Nat Cancer       Date:  2021-04-15

Review 3.  Small ring has big potential: insights into extrachromosomal DNA in cancer.

Authors:  Yihao Wang; Rui Huang; Guopei Zheng; Jianfeng Shen
Journal:  Cancer Cell Int       Date:  2021-04-26       Impact factor: 5.722

Review 4.  Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments.

Authors:  Marc G Denis; Jaafar Bennouna
Journal:  Cancer Manag Res       Date:  2020-12-08       Impact factor: 3.989

5.  Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases.

Authors:  Cai-Bao Jin; Ling Yang
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.